{"filing":{"accession_number":"0001193125-26-281051","cik":"0001815442","ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"d131538d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526281051/d131538d8k.htm"},"events":[{"id":13498,"run_id":11995,"accession_number":"0001193125-26-281051","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Kymera's Annual Meeting of Shareholders held on June 24, 2026. The filing reports the final voting tallies for three proposals: election of Class III directors (Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff), non-binding advisory vote on named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a material governance event affecting the composition of the board and auditor ratification.","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10643,"accession_number":"0001193125-26-281051","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Kymera's Annual Meeting of Shareholders held on June 24, 2026. The filing reports the final voting tallies for three proposals: election of Class III directors (Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff), non-binding advisory vote on named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a material governance event affecting the composition of the board and auditor ratification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:10:10.606068+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10643,"accession_number":"0001193125-26-281051","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Kymera's Annual Meeting of Shareholders held on June 24, 2026. The filing reports the final voting tallies for three proposals: election of Class III directors (Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff), non-binding advisory vote on named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a material governance event affecting the composition of the board and auditor ratification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:10:10.606068+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-24"}]}